

EXHIBIT B



RECOMBITEK® Equine West Nile Virus vaccine. Works fast. Lasts long.



RECOMBITEK® Equine West Nile Virus (WNV) vaccine uses a brilliant bit of technology to stimulate fast and lasting immunity¹ against this widespread, virulent and devastating infectious disease.

RECOMBITEK Equine WNV vaccine delivers targeted WNV protection.

- Made using Merial recombinant canarypox-vectored technology
- Contains only the specific WNV antigens (M and E) needed to stimulate immunity
- Demonstrates both humoral and cell-mediated immune responses^{1,2}
- Does not replicate or revert to virulence in the horse


Proven against West Nile virus.

Onset of immunity in just 26 days after initial dose³


- Horses receiving a single dose of RECOMBITEK Equine WNV and unvaccinated controls were challenged via bites from WNV-infected mosquitoes
- 89% of vaccinated horses were protected from viremia
- 33% of vaccinates had no neutralizing antibodies present, but were protected, indicating strong, specific priming of cell-mediated immunity
- 11% of vaccinates developed a transient viremia
- Viremia was detected in 80% of controls 72 to 120 hours post-challenge, confirming severity of challenge

Proven 345-day duration of immunity⁴

- Vaccinates and controls were challenged via bites from WNV-infected mosquitoes
- 90% of vaccinated horses were protected from viremia
- Viremia was detected in 84% of controls 24 to 72 hours post-challenge, confirming severity of challenge




*8 of 10 control horses had detectable viremia 72 to 120 hours after challenge by WNV-infected mosquitoes.



*5 of 6 control horses had detectable viremia 24 to 72 hours after challenge by WNV-infected mosquitoes.

Anamnestic response that measured both antibody and CMI²

- Proven rapid antibody and cell-mediated immune (CMI) responses
- Lasting anamnestic response that includes both antibodies and CMI — including CMI presence throughout study
- Proven continued ability of horses to respond to canarypox-vectored West Nile Virus vaccine after repeated injections
- Non-antigen-specific cells secreted IFN- γ suggesting an immune stimulation from the canarypox vector alone



RECOMBITEK uses canarypox-vectored vaccine technology for fast-acting, long-lasting protection against WNV.




Why protect horses with RECOMBITEK WNV?

- ♦ Full protection 14 days after primary two-dose series (only needed for naïve horses)¹
- ♦ Protection proven to last throughout the mosquito season¹
- ♦ Stimulates both humoral and cell-mediated immunity, putting both arms of the immune system into action^{1,2}
- ♦ Safe for use in foals 2 to 4 months of age and older³
- ♦ From Merial, a trusted leader in vaccine innovation and a maker of reliable equine vaccines, including IMRAB® for rabies

When to protect horses with RECOMBITEK Equine WNV vaccine.⁴

Foal	Yearling	Performance	Pleasure	Broodmare
1st dose: 2 to 4 months, or older	Annual*	Annual*	Annual*	Annual*

*For horses that have received a primary two-dose series.



¹Siger L, et al. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. *American Journal of Veterinary Research* 2004;65(11):1459-1462.

²El Garch H, Minke J, et al. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse. *Vet Immunol Immunopathol* 2008;123(2):230-239.

³Data on file at Merial. Study 02-092.

⁴Groenbaugh DA, et al. The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile Virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine. *Vet Ther* 2004;5(4):251-257.

⁵USDA-approved label claim.



1-888-MERIAL-1

Merial Family of Brands

RECOMBITEK, IMRAB, ZIMECTERIN and EQ/IOXX are registered trademarks, and POTOMAVAC and the HORSE HEAD LOGO are trademarks, of Merial.

GASTROGARD and ULCERGARD are registered trademarks of the AstraZeneca Group of Companies. West Nile-INNOVATOR is a registered trademark of Wyeth.

©2008 Merial Limited, Duluth, GA. All rights reserved. LAGEBWWB01R (8/08)

